# Clinical Study to Investigate Safety and Effects on Heart Rate, Blood Pressure, and Pharmacokinetic Interactions of ACT-334441

> **NCT02479204** · PHASE1 · TERMINATED · sponsor: **Viatris Innovation GmbH** · enrollment: 10 (actual)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** ACT-334441 2 mg
- **DRUG:** ACT-334441 4 mg
- **DRUG:** Placebo
- **DRUG:** Atenolol
- **DRUG:** Diltiazem ER

## Key facts

- **NCT ID:** NCT02479204
- **Lead sponsor:** Viatris Innovation GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-04-28
- **Primary completion:** 2016-05-01
- **Final completion:** 2016-05-01
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Based on results from the pilot phase, the study is terminated. No safety events leading to discontinuation were reported
- **Last updated:** 2025-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02479204

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02479204, "Clinical Study to Investigate Safety and Effects on Heart Rate, Blood Pressure, and Pharmacokinetic Interactions of ACT-334441". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02479204. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*